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ABSTRACT
Today, intraosseous access (IO) is not only an alternative method of administration of pharmacotherapy 
or fluids; it is often used in life-threatening conditions. Although previously, it was a method commonly 
used in paediatrics or in the military, for several years it has been advocated as the primary access point for 
patients in a critical condition. While this applies mainly to children, it may also include adults in a hospital 
setting, as well as in the emergency department. Oftentimes it is used when intravenous access is difficult 
or the patient is seriously ill. Many scientific circles at the American Heart Association (AHA) and European 
Resuscitation Council (ERC) approve this method.
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INTRODUCTION
The commencement of administering intraosseous 
drugs dates back to the early years of the twentieth 
century [1–4]. Today, we know that if intravenous 
access is difficult or impossible, intraosseous access 
should be considered. Currently, it also is a very 
effective method of administering drugs and fluids 
in adults. The concentration of drug administered 
intraosseously in most situations is comparable to 
the amount seen in the plasma when giving the 
drug intravenously (IV). Therefore, in recent years 
there has been an increased availability of mechani-
cal access to IO, resulting in its increased use. Today, 
intraosseous access is available to both adults and 
children (including infants) with a variety of IO ac-
cess points such as the sternum, the humerus, as 
well as both the proximal and distal portions of the 
tibia and radius [2]. Gaining access to the circula-
tory system is one of the most important tasks in 
patients suffering from sudden cardiac arrest. It is 
not easy to get a venous line in patients who, within 
the first two minutes of CPR, have failed to receive 
proper access. In such situations, accessing the bone 
marrow should be considered as the best alterna-
tive [5]. The choice and decision to use a particular 
device depends on the local protocol, as well as the 
skills and knowledge of the available equipment by 
the medical personnel. Often, however, the reality 
is that intraosseous devices are available but are 
not being used [3]. Of course, if possible, drugs in 
life-threatening conditions should be administered 
intravenously. However, always when complications 
arise, the immediate appropriate measure should 
be intraosseous [1]. Intraosseous access is obtained 
by injecting a needle directly into the marrow cavity 
using a specially designed device. This is an optional 
way to supply medication and fluids when there are 
IV complications or when it is simply impossible to 
access collapsed peripheral veins. The time it takes to 
introduce the needle in order to ensure contact with 
the marrow cavity is under a minute. With a properly 
placed intraosseous device, the infusion site can flow 
to 125 ml/min. In addition, it makes it possible to ac-
cess material for laboratory tests such as blood type, 
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gas analysis, morphology, haemoglobin, and electro-
lyte levels [6, 7]. The contraindications in establishing 
intraosseous access are fractures or other injuries at 
the proposed injection site, as well as local infection 
in the affected area. There is always a risk of compli-
cations that may arise when introducing an intraos-
seous injection. The most common are hematoma, 
inflammation, and bone fracture. Through the use 
of IO, bone marrow can be aspirated to check blood 
type and analyse the measurements of blood gases 
(gas levels are comparable to the blood gas levels in 
the central veins, provided intraosseous drugs were 
not earlier administered) [7]. Intraosseous access 
should be maintained only until a stable access to 
the venous vasculature is available. Ideally, needles 
should be removed in less than 24 hours [8, 9].
This paper is a literature meta-analysis of the 
last 10 years in the context of access to the vascular 
bed. The aim of the analysis is to describe the use 
of equipment, actions related to intraosseous access 
and its constraints. The data collected is divided into 
the following categories: indications, benefits and 
contraindications; technical rules; care during access; 
and possible complications. The collected literature on 
intraosseous vascular access supports intraosseous in-
jection as the main alternative to vascular access. The 
collected literature further supports how the connec-
tion and supply of drugs and fluids is quick and easy 
through the use of intraosseous vascular access.
General rules for accessing the vasculature
The use of intraosseous injections should follow 
the same rules as injections using intravenous ac-
cess. One should, however, emphasize adherence 
to the following key points in order to perform 
the procedure.
1. Sterilization of the skin at the access site;
2. Maintaining manual stabilization of the limbs 
(bones) during injection;
3. Aspiration directly after the introduction of the 
needle to confirm the correct positioning;
4. For conscious patients prior to administering 
medication or fluids, one should administer a lo-
cal anaesthetic (preferably lidocaine) at the intra-
osseous site in order to reduce the pain during 
subsequent infusions according to the principle: 
2 of 2 for 2 times (2 of 2 for 2 × 2). This means: 
2 ml of 2% lidocaine for 2 minutes 2 times;
5. Confirmation of proper access to the bone mar-
row by administration of 10 ml of fluid after 
administration of the drugs;
6. Patient records should state the execution of the 
intraosseous procedure;
7. Evaluation of the IO site for signs of extravasa-
tion.
Indications
According to the regulations, if intravenous access 
is difficult or impossible, one should always consid-
er intraosseous access. This means that with each 
life-threatening condition, when there is no possi-
bility of intravenous access, there is an obligation to 
seek an alternative route, or intraosseous access. The 
absolute indications include:
1. Paediatric patients in a critical condition;
2. Cardiac arrest in children and adults;
3. Failure to obtain intravenous access after two 
attempts (e.g. in victims with hypovolemia, 
in whom rapid intravenous access cannot be 
gained), or no possibility of the rapid establish-
ment of peripheral intravenous access [10–11].
Contraindications




4. Limb injury with damage to the vascular bed;
5. A previous attempt to establish intraosseous ac-
cess within 24 hours;
6. Relative contraindications include: difficulty in 
identifying the anatomical landmarks, in these 
patients. Moreover, IO access should be used 
with caution, as this may cause damage to near-
by structures [1–3, 5, 12].
Complications associated with obtaining 
intraosseous (IO) access:
1. Bruising;
2. Infection at the injection site;
3. Pain at the injection site;





8. Bone fracture, and splintering if the needle is 
too thick;
9. Inflammation at the site of the bone mar-
row cavity;
10. Bone marrow aplasia (destruction of bone mar-
row stromal connective tissue);
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2. Humerus:
It is recommended that the patient be in a sitting 
position. The upper limb which will enable IO access 
should be bent at the elbow, in order that the hand is 
touching the navel. One should then locate the core of 
the humerus, moving toward the shoulder. Near the 
shoulder one should find a protruding bone fragment 
— namely, the greater tubercle of the humerus. Using 
one’s other hand, one should feel for the protruding 
portion of the humerus in order to mark the injection 
site for IO access. In small children, finding the greater 
tuberosity of the humerus may be difficult (Fig. 2).
3. Manubrium:
Locate the manubrium, approximately 2 cm below 
the sternal notch, and insert at 90 degrees to the 
skin. The fluid flows into the internal mammary 
veins, then into the azygous veins, and finally into 
the central circulation [13–15].
EQUIPMENT FOR INTRAOSSEOUS ACCESS
Regarding the access and type of mechanism used 
for the injection, devices can be subdivided into 
three major types. 
11. Cardiac tamponade;
12. Extravasation of subcutaneous drugs;
13. Drug leakage from injection site;
14. Hypertension or pressure in the fascial space 
[10–12].
Conditions associated with executing 
inappropriate access
1. Puncture outside of the designated area;
2. Bone puncture;
3. Fluid transfused into the yellow marrow cavity of 
the bone marrow.
Access sites
Despite having a limited number of places where it 
is possible to achieve an access site, placement of 
a device depends essentially on the type of equip-
ment used. Some devices are limited to specific 
locations. The manubrium should be used primarily 
in military conditions. A bulletproof vest generally 
protects the chest; consequently it is subject to a de-
creased number of fractures. The upper and lower 
limbs are the places that are the most vulnerable to 
high-energy phenomena leading to common inju-
ries such as fractures and/or massive haemorrhage 
as a result of gunshot wounds, explosions leading 
to shrapnel lodging in the skin, amputations, de-
fragmentation tissue, all of which form contraindi-
cations to establishing IO access. Outlined below are 
suitable places for IO access:
1. Tibial Bone:
a) Proximal part of the tibia — locate the tuberosity 
of the tibia:
 — Adults — 2 cm, medially and 1 cm cranially 
from the tibial tuberosity (Fig. 1);
 — Paediatrics — 1–2 cm medially and around 
1 cm towards the foot from the tibial tuber-
osity to the flat portion of the bone;
 — Older children — slightly lower injection site 
than in paediatric patients;
b) Part of the distal tibia — locate the medial malle-
olus:
 — Adults — insertion site is located the width 
of two fingers above the upper edge of the 
ankle; 1–2 cm proximal to the base of the 
medial malleolus (4–5 cm above the end of 
the medial malleolus);
 — Paediatric patients — insertion site is located 
one finger width above the upper edge of 
the ankle.
FIGURE 1. Intraosseous access in location of Tibial Bone
FIGURE 2. Intraosseous access in location of Humerus 
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Manual Devices (manual trocar)
Requiring the use of large forces, manual devices are 
commonly used in hospital care and not used in emer-
gency care in a pre-hospital setting. They are recom-
mended for children in order to access the lower parts 
of the lower limbs. Although their ease of use and low 
cost are an advantage, the use of excessive force in 
relation to other devices is a drawback.
Jamshidi Needle
This device is limited to paediatric use on lower 
limb sites as excessive force is needed for insertion 
in adult patients (Fig. 3). These disposable intraos-
seous infusion needles provide one with a safe and 
simple technique in order to gain vascular access 
for delivering fluids and drugs to critically ill or in-
jured children. They feature a sharp lancet point 
to facilitate entry into the bone and Luer slip / Luer 
lock connection for a secure fit to any syringe. An 
adjustable guard helps one control the depth of 
needle insertion while a twist-off cap holds the stylet 
securely in place. Intraosseous infusion is recom-
mended only in life-threatening emergencies where 
vascular access is critical and conventional forms of 
access are not available or unobtainable. There are 
2 sizes: 15 gauge for those 9 months or older and 
18 gauge for those younger than 9 months [16].
Spring Devices (such as a gun)
The spring devices are used to aid penetration into 
the bone marrow. These are disposable devices used 
to introduce needles into the lower limb (tibia) or 
the upper lower limb (radius) and allow access to 
the sternum. These systems require training to en-
sure their proper use and inspect techniques.
BIG — Bone Injection Gun
The world’s first automatic, user-friendly IO device 
brings one safe, rapid IO access for the delivery 
of fluids and medications at flow rates similar to 
peripheral IV infusion (Fig. 4). With the help of 
a Bone Injection Gun, IO infusion can be established 
within seconds. The B.I.G. presents an easy and safe 
“position and press” mechanism. These are licensed 
for use in the proximal tibia and the humerus. The 
device is commonly colour coded; blue for adults, 
red for children and green for use by veterinary sur-
geons. Typically used at the upper tibia plateau, the 
technique is simple to learn through brief training. 
The BIG is rapidly becoming the device of choice for 
physicians and paramedics in emergency medical 
services, hospitals, armed forces, government agen-
cies, and tactical environments [17].
NIO Adult — New Intraosseous Device
The NIO is an automatic intraosseous device pack-
aged for safe, quick, and easy vascular access (Fig. 5). 
It is a simple, automatic intraosseous device ready to 
use for safe, quick, and easy vascular access. There 
are no drills, no batteries, nor extra parts. The NIO 
is small, light, and easy to use in even the most de-
manding situations. It is designed for easy injection 
into either the tibia or the humerus in all clinical 
settings and is intended for use on adults/those 
twelve years of age or older. The NIO is for use on 
the proximal tibia or the humeral head, and proved 
to be safe regarding the bone — resulting in zero 
incidence of bone fracture as observed by post-in-
sertion X-rays. Its features include the following:
1. Sterile — zero chance of cross-contamination;
2. Vascular access in as few as 10 seconds;
3. Disposable and single-use;
4. No external power source or battery needed;
5. Pocket-sized and lightweight — 3.5 oz.;
6. No maintenance required;
7. Patient-friendly, no exposed needle;
FIGURE 3. Jamshidi intraosseous needle
FIGURE 4. BIG — Bone Injection Gun
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European Resuscitation Council have approved it in 
the care and treatment of critically ill patients. The FAST 
IO 1 is also used and is dedicated for military medicine 
and Tactical Combat Casualty Care guidelines. 
The FAST1 can be placed and vascular access (es-
sentially equivalent to a central venous line) achieved 
in 10 seconds with medications reaching the heart 
within 30 seconds. Its features include the following:
1. It provides the quickest route to the heart of any 
IO access device and peripheral IV;
2. Exact placement is achieved every time;
3. Automatic depth control is provided for safe 
delivery above the lungs and heart;
4. It is easy to use, even for new medical profes-
sionals;
5. It is a sterile, single-use, disposable product with 
no risk of cross-contamination;
6. It is flexible with soft, low-profile, secure tubing;
7. Its lightweight design allows its portability in 
medic packs [19–21].
Drill-based system (drill)
These devices are easy to use, requiring less training. 
Battery-powered drills enable a broader range of 
access points to the injection site. They consist of 
a reusable drill and disposable needles.
EZ-IO — Easy Intraosseous
This is a handheld drill device, which consists of 
a power driver and needle set (Fig. 6). There are 
three different needle and stylet combinations, suit-
ed to different patient sizes. There are needles for 
patients weighing 3–39 kg, more than 40 kg, and 
a large needle for patients with excess soft tissue. Its 
features include the following:
1. The EZ-IO Intraosseous Vascular Access System 
is a fast vascular access option that provides 
peripheral venous access with central venous 
8. Assembled and ready to use in a package;
9. A 5-year shelf life;
10. 2 sizes — adult and paediatric [18].
FAST1 Sternal IO
As a highly effective alternative to traditional peripher-
al intravenous access, FAST1 gives one the critical abili-
ty to quickly establish vascular access, as well as rapidly 
and easily deliver emergency fluids and medications 
into the vascular system through the bone marrow 
of the manubrium. Safe to use in patients 12 years of 
age and older, FAST1 can be effectively used during 
CPR and when a cervical spine collar is in place.
Reasons to choose FAST1 include the following:
1. FAST1 is always ready to use and does not re-
quire batteries;
2. As the sternum is easier to locate than long 
bones, the speed and ease of finding the access 
site is increased;
3. It provides reliable and consistent access with 
automatic depth adjustment;
4. Easy to learn and difficult to make mistakes, even 
for novice users;
5. The injection site and the manner of its estab-
lishment and location makes it safe and difficult 
to remove in unwanted circumstances, e.g. dur-
ing transport;
6. It provides less pain for the patient both during 
insertion and the administration of drugs. In 
most cases, lidocaine is not required;
7. It consists of a compact and lightweight de-
sign.
The benefits of the FAST1
The FAST1 allows for the use of any fluid or medication 
that can be injected intravenously. The American Heart 
Association, Advanced Trauma Life Support and the 
FIGURE 5. NIO Adult — New Intraosseous Device
FIGURE 6. EZ-IO — Easy Intraosseous access device
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catheter performance, avoiding unnecessary cen-
tral line placement and, thus, the risk of central 
line infection;
2. The EZ-IO Intraosseous Vascular Access System 
uses the intraosseous space of the humerus, 
tibia, and distal femur (paediatrics) as a large, 
non-collapsible vein;
3. The EZ-IO needle has a uniquely designed needle 
tip that drills a hole in the bone the same size as 
the needle, minimizing the risk of extravasation 
or dislodgement;
4. Insertion is gentle, fast and relatively painless, 
and is particularly beneficial for patients who re-
quire multiple IV sticks to obtain vascular access 
for medication [22].
According to the manufacturers, each of the 
methods employed through these devices provide 
quick access and make it possible to get the flow to 
125 ml/min. The same drugs given intravenously can 
be safely given through intraosseous insertion. To pro-
mote high flow values with fluid therapy after using 
intraosseous injection, a cuff is used in instances of 
quick transfusion. It is possible to obtain a rate greater 
than 125 ml/min, which provides a chance to increase 
injection transfusions of up to 1,000 ml in 4 minutes 
(2 × 125 ml = 250 ml = 1000 ml over 4 min).
DISCUSSION
A study done on Transported Helicopter Emergency 
Medical teams assessed that from 780 patients, 
intraosseous access was used 40 times, meaning 
in 5.1% of cases. The device used was the BIG 
whose efficacy in children (age < 16 years) was 71% 
(10/14) and 73% in adults (19/26). In this study no 
serious complications were noted [23].
In a prospective study conducted by Gazin et al., 
lasting one year and with prehospital staff access-
ing vascular entry 4,666 times, intraosseous access 
was performed 39 times, which accounted for only 
0.84% of the total number of injections. Of these 
39 injections, 30 included patients in cardiac arrest 
while 9 were performed in patients with preserved 
perfusion. The effectiveness of forming an access on 
the first attempt was 84% [24].
In a study by Schwartz et al., of 189 cases of 
EMS employees employing IO in a prehospital set-
ting over a period of 4 years, as much as 56% were 
related to cardiovascular morbidity. Moreover, 12% 
were trauma-related, 11% respiratory-related and 
the rest, which made up to 21% of patients [25].
Leidel et al. performed a study where two intra-
osseous devices were compared namely, the BIG and 
EZ-IO. The difference in the use of both devices was 
found not to be statistically significant and no sig-
nificant complications were observed. Both devices 
were used and compared in 20 trials. The efficacy 
of the use of the BIG reached 80% while that of the 
EZ-IO was 90% [26].
In an interventional, randomized, crossover, sin-
gle-centre cadaver study, a semi-automatic spring-
load driven NIO access device was investigated. In 
total, 84 paramedics with less than 5 years of experi-
ence in the Emergency Medical Services participated 
in the study. The trial was performed on 42 adult ca-
davers. In each cadaver, 2 IO accesses to the humerus 
head, and 2 IO accesses to the proximal tibia were 
obtained. The success rate of the first IO attempt was 
89.3% (75/84) for tibial access, and 73.8% for humer-
al access. Tibial IO access is easier and faster to put in 
place than humeral IO access. Humeral IO access may 
be an alternative method to tibial IO access [27].
In a study comparing intraosseous devices based 
on the time needed to obtain proper access to the 
marrow, the BIG, FAST 1 and Jamshidi Needle were 
compared. The quickest method proved to be the 
method involving the manual trocar (Manual tro-
car — Jamshidi Needle) which achieved an average 
access time of 38 seconds, the next being the BIG 
and the FAST with 49 seconds and 62 seconds, re-
spectively. The efficacy of the total devices used was 
80% in adults and in children 86%. No significant 
difference was observed in their effectiveness, nor 
in the number of complications [28].
CONCLUSION
In recent years, there have been a number of devic-
es that have come on the market providing quick 
and easy intraosseous access. This ensures comfort 
for medical personnel conducting the procedure 
and the ability and reliability of the administration 
of pharmacotherapy in life-threatening conditions, 
especially in children and patients during cardiac 
arrest. For two-person medical rescue teams, this is 
a key way of cutting down the time needed to gain 
access to the vascular bed and to provide patients 
with analgesics and life-support pharmacotherapy. 
In conjunction with a tourniquet, IO access ena-
bles rapid fluid replacement. Another advantage of 
intraosseous access is the ability to perform basic 
tests for blood gases and to determine blood type. 
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However, their main disadvantage is the high costs 
of the intraosseous needles and sets. IO access is an 
alternative to venous punctures provided by appro-
priately trained medical personnel who require regu-
lar training in order to maintain the skills associated 
with obtaining appropriate access and the ability to 
provide pharmacotherapy. Intraosseous access, as 
a form of contact with the cardiovascular system, 
was officially recognized by the AHA and ERC in 
2010 as an alternative to intraventricular (IV) access 
and is regarded as providing safe and effective ac-
cess to the vasculature. Complications are relatively 
rare, and it is important that it can be successfully 
used in virtually all age groups and as a tool to ad-
minister any type of pharmacotherapy that is used 
to access the vasculature and effectively treat pa-
tients in hypovolemic shock with fluids. 
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